SOPH

SOPHiA GENETICS SA

NASDAQ· Healthcare· Health Information Services

$8.14-8.74%

Key metrics

Market cap: $692.94M
P/E: —
Forward P/E: —
P/B: 8.3x
Dividend yield: —
EPS: -$1.06
ROE: -101.22%
Profit margin: -93.86%
Revenue growth: +27.20%
Beta: 0.92
52-week high: $8.98
52-week low: $3.10

History

How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.

Equity, revenue and profitEquityRevenueNet income

The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.

Revenue4 years

Net debtDebt minus cash — below zero means more cash than debt

Investors holding this

Major managers that reported this stock in their latest 13F.

About the company

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.

Employees: 415
Headquarters: Rolle, Switzerland
Website: sophiagenetics.com

Company description provided by Yahoo Finance.